Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult2. fázis

Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management

A legfontosabb adatok

Ki végzi
British Columbia Cancer Agency
Hol
Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
2. fázis
Résztvevők
90 fő, tervezett
Kezdés
2026. okt. 30.
Várható befejezés
2032. okt. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Treatment De-escalation
  • Additional Treatment
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
18 év felett
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 9 feltétel megnézéseKevesebb

Ki vehet részt

  • Had primary surgery consisting of hysterectomy (any surgical approach) and bilateral salpingo-oophorectomy
  • Lymph node dissection can be performed as per institutional practice (sentinel node biopsy or full)
  • Had no macroscopic residual disease after surgery; Meet the molecular and pathological criteria (1, 2, or 3) as determined or identified by their local oncologist and pathologist:
  • (Molecular) NSMP ER strong positive:; Endometrial site; Low grade endometrioid (grade 1-2); <50% myometrial invasion (FIGO 2009 stage IA); Absence of substantial lymphovascular invasion (LVI); Ovarian site; Low grade endometrioid (grade 1-2); bilateral (stage IB),; intraoperative spill (stage ICI),; preoperative rupture (stage IC2),; surface involvement (stage IC2)
  • (Molecular) POLEmut; Endometrial site; FIGO 2009 stage IA or IB (regardless of grade, histotype, myoinvasion or LVI); Ovarian site; Low grade endometrioid (grade 1-2); bilateral (stage IB),; intraoperative spill (stage ICI),; preoperative rupture (stage IC2),; surface involvement (stage IC2),
  • (Molecular) MSH2, MSH6, or PMS2 loss (MMRd without MLH1 promoter hypermethylation); Endometrial site; FIGO 2009 stage IA or IB (regardless of grade, histotype, myoinvasion or LVI); Ovarian site; Low grade endometrioid (grade 1-2); bilateral (stage IB),; intraoperative spill (stage ICI),; preoperative rupture (stage IC2),; surface involvement (stage IC2),

Ki nem vehet részt

  • Individuals with MMRd MLH1 promoter hypermethylation or p53abn status in their ovarian or endometrial tumour
  • Individuals with ER negative-low status in the endometrium
  • Individuals with any additional sites of metastases

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Patients with co-existent endometrial and ovarian carcinomas (CEOCs) are treated inconsistently due to a lack of clear standardized treatment guidelines. Patients may be over-treated and face substantial physical side effects and financial challenges due to additional chemotherapy or radiation appointments. Previous retrospective research has shown that using specific molecular and pathologic criteria to stratify patients' CEOC tumours can identify patients at very low risk of cancer recurrence (during an average 6 years of follow-up), with no demonstrated benefit of additional treatment after surgery.

A teljes eredeti leírásKevesebb

The goal of this study is to determine the safety of receiving no additional treatment (i.e. no chemotherapy or radiation) after surgery in patients diagnosed with a co-existent endometrial and ovarian cancer (CEOC) meeting highly selective molecular and pathologic criteria. Patients with CEOC who also meet predefined molecular criteria (low risk POLEmut, ER+NSMP, or MSH2/MSH6/PMS2 loss without MLH1 promoter hypermethylation in the endometrium and ovary) and pathology criteria (see schema) are eligible to participate. Patients may choose, or be directed by their physician to receive no additional treatment after surgery or to receive additional treatment.

To determine the safety of this approach, the study team will evaluate pelvic recurrence (primary) rate, as well as vaginal and distant recurrences, recurrence-free and disease- specific, and overall survival, quality of life, and health economic metrics among patients who do, and do not receive additional treatment after surgery.

Study design is pragmatic, designed to match recommended standard of care as closely as possible. Patients will have regular follow-up appointments with their oncologist every 4 months for 3 years as part of their medical care. During this time, patients will complete quality of life surveys at baseline, 4, 12, 24, and 36 months. Baseline imaging, and imaging at completion of 3-years are required.

A vizsgálat 2 csoportja

  • Treatment De-escalationA vizsgált kezelés

    After undergoing surgery, patients elect to not receive any further treatment (such as radiation or chemotherapy) to treat their cancer. Instead their condition will be closely followed by their oncologist for 3 years.

  • Additional TreatmentEgyéb csoport

    After undergoing surgery, patients elect to receive additional treatment (such as radiation or chemotherapy) to treat their cancer. The type of additional treatment received will be determined by the patient's oncologists in conjunction with the patient. These patients will be closely followed by their oncologist for 3 years.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Co-Existent Endometrial and Ovarian Carcinoma: Optimization of Treatment Through Molecular and Pathological Refinement
A regiszteradat frissítve
2026. november 16.